Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Injections 3Doxorubicin 3anlotinib 2toripalimab 1pemigatinib 1pazopanib 1montelukast 1liposomal doxorubicin 1eribulin 1chlorhexidine gluconate 1camrelizumab 1bexmarilimab 1apatinib 1X-Rays 1Trabectedin 1Temozolomide 1Tablets 1Sodium Chloride 1Radiotherapy 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Negative-Pressure Wound Therapy 1KP 1339 1Ipilimumab 1Immunotherapy 1Heavy Ion Radiotherapy 1Granulocyte Colony-Stimulating Factor 1Epirubicin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Sarcoma × pemigatinib × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡